RXRX Stock: Price, Earnings History and SEC Filings
Recursion Pharmaceuticals, Inc. (RXRX) last traded at $4.03, down 4.95% on the latest session and down 2.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.25 against an analyst estimate of $-0.23, a miss of 8.7%.
$4.03 -4.95%
1 month-2.42%
52-week high$5.76
52-week low$2.77
Volume24.41M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RXRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.25 | $-0.23 | -8.70% |
| Mar 2026 | May 6, 2026 | $-0.22 | $-0.30 | +26.67% |
| Dec 2025 | Feb 25, 2026 | $-0.21 | $-0.28 | +25.00% |
| Sep 2025 | Nov 5, 2025 | $-0.36 | $-0.38 | +5.26% |
RXRX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RXRX
SEC filing data is not available right now. You can search for RXRX on SEC EDGAR.
RXRX news
- 1 Big Winner and 1 Loser From the Upcoming Anthropic IPOOct 31, 2026 · fool.com
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsOct 30, 2026 · finance.yahoo.com
- Absci Sinks 8%, Schrödinger and Recursion Slide as AI Drug Discovery Stocks Give Back RallyOct 30, 2026 · tikr.com
- Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?Oct 29, 2026 · finance.yahoo.com
- Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 28, 2026 · finance.yahoo.com
- Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to ConsiderOct 26, 2026 · finance.yahoo.com
- Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3Oct 26, 2026 · finance.yahoo.com
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is a US-listed public company on Nasdaq.